Rocket


Overview
Financials
News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Erytech Pharma S.A. (ERYP) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/11/2023 6-K Quarterly results
10/05/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"PHAXIAM Therapeutics and Vetophage Announce Strategic Research Collaboration",
"PHAXIAM Receives Compliance Notice from Nasdaq"
09/26/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"CERTIFICATION OF THE PERSON RESPONSIBLE FOR THE HALF-YEAR FINANCIAL",
"PHAXIAM Provides Business and Financial Update For the First Half of 2023"
07/27/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"PHAXIAM Therapeutics announces a reverse share split of its shares Reverse share split by the exchange of ten existing shares with a par value of ten-euro cents for one new share with a par value of one euro Publication of the reverse share split notice in the BALO: July 31st , 2023 Start of the reverse share split: August 16 th , 2023 Effective date of the reverse share split : September 18 th , 2023 Lyon and Cambridge , July 27 th , 2023 - PHAXIAM Therapeutics , today announces the implementation of the reverse share split of the shares composing the Company's share capital, by decision of the Chief Executive Officer on July 27 th , 2023, following the sub-delegation granted by the Board of Directors on June 23rd , 2023, taken in accordance with the twenty-third extraordinary resolution ..."
06/30/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Phaxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXM"
06/12/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ERYTECH Responds to Akkadian’s Disinformation"
05/26/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 23, 2023"
05/24/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Document d'exemption (English translation)",
"PHERECYDES 2022 Annual Financial Report (English translation)"
05/16/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ERYTECH Provides Update on the Announced Combination with PHERECYDES"
05/10/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ERYTECH Provides Business and Financial Update for the First Quarter of 2023"
04/18/2023 6-K Quarterly results
03/23/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2022"
11/22/2022 6-K Quarterly results
10/14/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ERYTECH Announces Receipt of Nasdaq Notice"
09/12/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"CERTIFICATION OF THE PERSON RESPONSIBLE FOR THE HALF-YEAR FINANCIAL"
08/25/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ERYTECH Provides Regulatory Update"
06/28/2022 6-K Quarterly results
05/25/2022 6-K Quarterly results
05/13/2022 6-K Quarterly results
05/02/2022 6-K Quarterly results
04/28/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Asset Purchase Agreement",
"Asset Purchase Agreement"
04/25/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ERYTECH Sells U.S. Manufacturing Facility and Enters Long-Term Supply Agreement with Catalent"
03/15/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2021"
02/10/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ERYTECH Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases"
01/27/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ERYTECH Announces Presentation of Results of Two Clinical Trials of Eryaspase"
12/16/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Opinion of Gide Loyrette Nouel A.A.R.P.I",
"Form of Subscription Agreement, between ERYTECH Pharma S.A. and the investor named therein",
"Terms and Conditions of the Warrants, between ERYTECH Pharma S.A. and the investor named therein",
"Placement Agency Agreement, by and between ERYTECH Pharma S.A. and H.C. Wainwright & Co., LLC",
"ERYTECH Announces Presentation of Results of Expanded Access Program in ALL at 2021 ASH Annual Meeting and Acceptance of Two Abstracts at ASCO GI",
"ERYTECH Announces $7.85 Million Registered Direct Offering Lyon and Cambridge, MA , December 14, 2021 - ERYTECH Pharma , a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it has entered into a definitive agreement with Armistice, a health-care focused institutional and accredited investor, for the purchase and sale of 769,608 units , each Unit consisting of four ordinary shares in the form of American Depositary Shares and three warrants, each to purchase one ordinary share , in a registered direct offering to specified categories of investors, described below. The subscription price for one Unit is $10.20 , corresponding to $2.55 per ADS and associated 0.75 warrant. Each ADS ..."
11/30/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ERYTECH Secures US Patent Directed to Sequential Use of Methioninase & Asparaginase against Solid Tumors"
11/16/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"EX-99.-1"
10/25/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ERYTECH Announces Results from TRYbeCA-1 Phase 3 Trial of Eryaspase in Patients with Second-line Advanced"
10/05/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ERYTECH Announces Maximum Tolerated Dose Declared in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer"
09/21/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2021"
09/20/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"CERTIFICATION OF THE PERSON RESPONSIBLE FOR THE HALF-YEAR FINANCIAL"
07/30/2021 6-K Quarterly results
07/26/2021 6-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy